Releases
ADAP
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest Adaptimmune (ADAP) stock and general news. This information may help you make smarter investment decisions.
About ADAP
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company that focuses on the development of novel cancer immunotherapy products for people with cancer. The Company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. The Company’s clinical trials include SPEARHEAD-1 Phase II Trial with afamitresgene autoleucel (afami-cel), SPEARHEAD-2 Phase II trial with afami-cel, SURPASS Phase I trial with ADP-A2M4CD8, ADP-A2AFP Phase I trial and Afami-cel Phase I trial radiation sub-study.